Literature DB >> 22383743

Activation of the NOTCH1 pathway in chronic lymphocytic leukemia.

Valentina Gianfelici.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22383743      PMCID： PMC3291584          DOI： 10.3324/haematol.2012.061721

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

1.  NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL.

Authors:  Paolo Sportoletti; Stefano Baldoni; Laura Cavalli; Beatrice Del Papa; Elisabetta Bonifacio; Raffaella Ciurnelli; Alain Sylvin Bell; Ambra Di Tommaso; Emanuela Rosati; Barbara Crescenzi; Cristina Mecucci; Isabella Screpanti; Pierfrancesco Marconi; Massimo F Martelli; Mauro Di Ianni; Franca Falzetti
Journal:  Br J Haematol       Date:  2010-08-31       Impact factor: 6.998

2.  A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation.

Authors:  Mauro Di Ianni; Stefano Baldoni; Emanuela Rosati; Raffaella Ciurnelli; Laura Cavalli; Massimo F Martelli; PierFrancesco Marconi; Isabella Screpanti; Franca Falzetti
Journal:  Br J Haematol       Date:  2009-07-10       Impact factor: 6.998

Review 3.  Recent insights into the role of Notch signaling in tumorigenesis.

Authors:  Kevin G Leong; Aly Karsan
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

4.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.

Authors:  Xose S Puente; Magda Pinyol; Víctor Quesada; Laura Conde; Gonzalo R Ordóñez; Neus Villamor; Georgia Escaramis; Pedro Jares; Sílvia Beà; Marcos González-Díaz; Laia Bassaganyas; Tycho Baumann; Manel Juan; Mónica López-Guerra; Dolors Colomer; José M C Tubío; Cristina López; Alba Navarro; Cristian Tornador; Marta Aymerich; María Rozman; Jesús M Hernández; Diana A Puente; José M P Freije; Gloria Velasco; Ana Gutiérrez-Fernández; Dolors Costa; Anna Carrió; Sara Guijarro; Anna Enjuanes; Lluís Hernández; Jordi Yagüe; Pilar Nicolás; Carlos M Romeo-Casabona; Heinz Himmelbauer; Ester Castillo; Juliane C Dohm; Silvia de Sanjosé; Miguel A Piris; Enrique de Alava; Jesús San Miguel; Romina Royo; Josep L Gelpí; David Torrents; Modesto Orozco; David G Pisano; Alfonso Valencia; Roderic Guigó; Mónica Bayés; Simon Heath; Marta Gut; Peter Klatt; John Marshall; Keiran Raine; Lucy A Stebbings; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Ivo Gut; Armando López-Guillermo; Xavier Estivill; Emili Montserrat; Carlos López-Otín; Elías Campo
Journal:  Nature       Date:  2011-06-05       Impact factor: 49.962

5.  Direct inhibition of the NOTCH transcription factor complex.

Authors:  Raymond E Moellering; Melanie Cornejo; Tina N Davis; Cristina Del Bianco; Jon C Aster; Stephen C Blacklow; Andrew L Kung; D Gary Gilliland; Gregory L Verdine; James E Bradner
Journal:  Nature       Date:  2009-11-12       Impact factor: 49.962

6.  Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines.

Authors:  Shuangyou Liu; Stephen Breit; Sven Danckwardt; Martina U Muckenthaler; Andreas E Kulozik
Journal:  Ann Hematol       Date:  2008-12-05       Impact factor: 3.673

7.  Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells.

Authors:  Emanuela Rosati; Rita Sabatini; Giuliana Rampino; Antonio Tabilio; Mauro Di Ianni; Katia Fettucciari; Andrea Bartoli; Stefano Coaccioli; Isabella Screpanti; Pierfrancesco Marconi
Journal:  Blood       Date:  2008-09-16       Impact factor: 22.113

8.  In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.

Authors:  Kim De Keersmaecker; Idoya Lahortiga; Nicole Mentens; Cedric Folens; Leander Van Neste; Sofie Bekaert; Peter Vandenberghe; Maria D Odero; Peter Marynen; Jan Cools
Journal:  Haematologica       Date:  2008-03-05       Impact factor: 9.941

9.  Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation.

Authors:  Giulia Fabbri; Silvia Rasi; Davide Rossi; Vladimir Trifonov; Hossein Khiabanian; Jing Ma; Adina Grunn; Marco Fangazio; Daniela Capello; Sara Monti; Stefania Cresta; Ernesto Gargiulo; Francesco Forconi; Anna Guarini; Luca Arcaini; Marco Paulli; Luca Laurenti; Luigi M Larocca; Roberto Marasca; Valter Gattei; David Oscier; Francesco Bertoni; Charles G Mullighan; Robin Foá; Laura Pasqualucci; Raul Rabadan; Riccardo Dalla-Favera; Gianluca Gaidano
Journal:  J Exp Med       Date:  2011-06-13       Impact factor: 14.307

10.  Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.

Authors:  Miguel Aste-Amézaga; Ningyan Zhang; Janet E Lineberger; Beth A Arnold; Timothy J Toner; Mingcheng Gu; Lingyi Huang; Salvatore Vitelli; Kim T Vo; Peter Haytko; Jing Zhang Zhao; Frederic Baleydier; Sarah L'Heureux; Hongfang Wang; Wendy R Gordon; Elizabeth Thoryk; Marie Blanke Andrawes; Kittichoat Tiyanont; Kimberly Stegmaier; Giovanni Roti; Kenneth N Ross; Laura L Franlin; Hui Wang; Fubao Wang; Michael Chastain; Andrew J Bett; Laurent P Audoly; Jon C Aster; Stephen C Blacklow; Hans E Huber
Journal:  PLoS One       Date:  2010-02-08       Impact factor: 3.240
View more
  8 in total

1.  Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.

Authors:  Paolo Strati; Koichi Takahashi; Christine B Peterson; Michael J Keating; Philip A Thompson; Naval G Daver; Nitin Jain; Jan A Burger; Zeev Estrov; Susan M O'Brien; Hagop M Kantarjian; William G Wierda; P Andrew Futreal; Alessandra Ferrajoli
Journal:  Blood Adv       Date:  2019-05-14

2.  Metadherin contributes to the pathogenesis of chronic lymphocytic leukemia partially through Wnt/β-catenin pathway.

Authors:  Pei-Pei Li; Li-Li Feng; Na Chen; Xue-Ling Ge; Xiao Lv; Kang Lu; Mei Ding; Dai Yuan; Xin Wang
Journal:  Med Oncol       Date:  2015-01-10       Impact factor: 3.064

3.  Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.

Authors:  Jose D Sandoval-Sus; Julio C Chavez; Samir Dalia; Syeda Mahrukh Hussnain Naqvi; Chetasi Talati; Lisa Nodzon; Mohamed A Kharfan-Dabaja; Javier Pinilla-Ibarz
Journal:  Leuk Lymphoma       Date:  2017-06-22

4.  Hes1 Controls Proliferation and Apoptosis in Chronic Lymphoblastic Leukemia Cells by Modulating PTEN Expression.

Authors:  Qikai Zhang; Zongsi Zhu; Jiaqiang Guan; Yingying Hu; Wenjin Zhou; Wanchun Ye; Bijing Lin; Shanshan Weng; Yuemiao Chen; Cuiping Zheng
Journal:  Mol Biotechnol       Date:  2022-06-15       Impact factor: 2.860

5.  Lack of Associations between TLR9 and MYD88 Gene Polymorphisms and Risk of Chronic Lymphocytic Leukemia

Authors:  Yasser B.M Ali; Rasha M Foad; Essam Abdel-Wahed
Journal:  Asian Pac J Cancer Prev       Date:  2017-12-29

6.  Clinical Value of NOTCH1 Mutations Detection among Chronic Lymphocytic Leukemia Patients.

Authors:  Salah Aref; Mohamed El-Agder; Osama Salama; Tarek Abouzeid; Mohamed Sabry
Journal:  Asian Pac J Cancer Prev       Date:  2020-05-01

7.  Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia.

Authors:  Shulan Tian; Henan Zhang; Pan Zhang; Michael Kalmbach; Jeong-Heon Lee; Tamas Ordog; Paul J Hampel; Timothy G Call; Thomas E Witzig; Neil E Kay; Eric W Klee; Susan L Slager; Huihuang Yan; Wei Ding
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

8.  Mannose-binding lectin 2 (MBL2) gene polymorphisms do not influence frequency of infections in chronic lymphocytic leukemia patients.

Authors:  Katarina Holanda; Antonio Roberto Lucena-Araujo; Adônis Quintas; Taciana Mendonça; Aleide Lima; Luydson Richardson Vasconcelos; Patrícia Moura; Maria Cavalcanti; Cíntia Machado; Aderson Silva Araújo; Marcos Andre Bezerra
Journal:  Rev Bras Hematol Hemoter       Date:  2014
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.